Compounded Semaglutide: The FDA Crackdown, What's Still Legal, and Your 4 Options

The FDA ended large-scale compounded semaglutide production in 2025 after removing the drug from its shortage list, affecting an estimated 3–4 million patients who were paying $99–$249/month for compounded versions of Wegovy and Ozempic. As of April 2026, outsourcing facilities (503B pharmacies) cannot legally compound bulk semaglutide for weight loss, and enforcement is active. The most viable alternatives are compounded tirzepatide ($149–$299/month, still legal as tirzepatide remains on the shortage list), brand Wegovy with manufacturer savings programs, and oral Foundayo (orforglipron). This guide explains exactly what happened, what narrow exceptions remain, and which option is best for your situation.

What Happened: The FDA Crackdown Timeline

The legal status of compounded GLP-1 medications changed significantly over the past 18 months. Here is the timeline of how it unfolded:

The core issue: semaglutide shortages were the legal basis for compounding exemptions under the FDA's Drug Shortage Compounding Policy. Once Novo Nordisk resolved its manufacturing capacity issues and FDA removed semaglutide from the shortage list, that legal basis evaporated for most compounders.

Is Any Compounded Semaglutide Still Legal?

Yes — but under narrow circumstances that apply to very few patients. Under Section 503A of the Federal Food, Drug, and Cosmetic Act, a licensed prescriber can still work with a patient-specific compounding pharmacy to obtain compounded semaglutide if:

• •Documented allergy — The patient has a verified allergy to an inactive ingredient in commercial Wegovy or Ozempic (e.g., a specific preservative or filler) that is not present in the compounded formulation.
• •Non-commercially-available dose — The patient medically requires a specific dose or concentration that is not available in the branded product's approved strengths.
• •Provider judgment + prescription — A licensed prescriber must document the medical necessity and write a patient-specific prescription for that individual, not a standing order for a patient population.

Additionally, the FDA has signaled it intends to restrict even some 503A peptide-based compounding in 2026, potentially adding further limitations. Check our safety center for the latest regulatory updates.

Your 4 Options as a Former Compounded Semaglutide Patient

If you were relying on compounded semaglutide, you have four realistic paths forward. Here is a quick comparison before we detail each:

Option 1: Switch to Compounded Tirzepatide (Best for Most Patients)

Tirzepatide — the active ingredient in Zepbound and Mounjaro — remains on the FDA drug shortage list as of April 2026. This means compounding pharmacies can still legally produce it. And there is a compelling clinical case for the switch: in the SURMOUNT-1 trial, tirzepatide produced 20.9% mean weight loss at the highest dose, compared to 14.9% for semaglutide in the STEP 1 trial — roughly 40% more weight loss on paper.

Compounded tirzepatide through telehealth starts at $149/month all-in (medication + consultation + shipping). Our top-rated providers for compounded tirzepatide:

For a full comparison, see our compounded tirzepatide guide and cheapest tirzepatide rankings. Both Enhance MD and Sprout Health have established compounding pharmacy partnerships and carry verified 503A/503B credentials.

Option 2: Brand-Name Wegovy with Manufacturer Savings

Brand Wegovy (semaglutide 2.4mg weekly injection) is FDA-approved and widely available through telehealth providers and traditional pharmacies. The list price is approximately $1,349/month, but several programs significantly reduce that cost:

• •Wegovy Savings Card — If you have commercial insurance that covers Wegovy, the Novo Nordisk savings card reduces your copay to as low as $0/month for the first month and up to $500/month savings. Cannot be used with Medicare, Medicaid, or any government insurance.
• •NovoCare Patient Assistance Program — Free Wegovy for patients at or below 400% of the federal poverty level (approximately $60,000/year for a single person in 2026). Apply at novonordisk-us.com. Income and residency verification required.
• •GoodRx coupons — Reduce out-of-pocket Wegovy cost to $800–$950/month without insurance. Not ideal long-term, but useful as a bridge while pursuing insurance coverage.
• •Telehealth providers with insurance verification — Several providers in our rankings will verify your insurance coverage and help with prior authorization appeals if you are denied.

If you had insurance coverage for compounded semaglutide through a telehealth provider, note that coverage for brand Wegovy often requires a separate prior authorization. Our insurance lookup tool can help you check your plan's GLP-1 coverage status.

Option 3: Foundayo (Oral Orforglipron) — The Pill Alternative

Foundayo (orforglipron) is a newly FDA-approved oral GLP-1 receptor agonist that was approved for chronic weight management in early 2026. Unlike injectable semaglutide or tirzepatide, it is taken once daily as a pill — no compounding, no injections, standard pharmacy dispensing.

• •Phase 3 trial results: 9.4–14.7% weight loss at 36 weeks depending on dose — less than injectable semaglutide or tirzepatide, but meaningful
• •Cost: ~$349/month list price; manufacturer savings programs in development
• •Key advantage: Oral route, no cold storage required, available at standard retail pharmacies
• •Key limitation: Lower weight loss efficacy than injectable GLP-1s; no generic compounded version yet

Read the full analysis in our Foundayo guide 2026 and see how it compares head-to-head in our Foundayo vs Wegovy pill article. Foundayo is a strong choice for patients who prioritized the convenience of compounded semaglutide over raw efficacy.

Option 4: Appeal Your Insurance Denial

If your insurer previously denied GLP-1 coverage, the landscape has changed. As of 2026, most major commercial insurers cover at least one GLP-1 medication for obesity when medical necessity is documented. A strong appeal should include:

• •BMI documentation — A BMI ≥30, or BMI ≥27 with at least one weight-related comorbidity (Type 2 diabetes, hypertension, obstructive sleep apnea, cardiovascular disease)
• •Prior treatment documentation — Evidence of failed attempts with at least one other weight management approach
• •Letter of medical necessity — From your prescribing provider, ideally a physician or NP, documenting clinical need
• •Specific drug requested — Appeal for the specific covered GLP-1 on your formulary; use your insurer's preferred drug if one is listed

Use our insurance lookup tool to check GLP-1 coverage policies by major insurer, or our eligibility checker to see if you meet the criteria insurers typically require.

How to Choose Between Your Options

Your best path depends primarily on your insurance situation and weight loss goals:

Not sure which provider to use? Take our 7-question match quiz — it factors in your budget, insurance status, injection preference, and health goals to recommend the best provider for your situation. Or use the cost calculator to see a side-by-side price comparison.

What This Means for Semaglutide vs. Tirzepatide

The practical effect of the FDA crackdown is to steer most compounded GLP-1 users toward tirzepatide. This is not necessarily bad news — tirzepatide consistently outperforms semaglutide in clinical trials. Our full semaglutide vs tirzepatide comparison covers the efficacy, cost, and side effect differences in detail.

The price difference between former compounded semaglutide ($99–$200/mo) and compounded tirzepatide ($149–$299/mo) is real but modest compared to the higher weight loss ceiling. Most patients who switch report comparable or improved results. See our brand vs compounded GLP-1 guide for more context on the regulatory framework.

Frequently Asked Questions

Is compounded semaglutide completely illegal in 2026?

Not completely. Large-scale 503B outsourcing facility compounding of semaglutide is banned. Small 503A pharmacies can still compound patient-specific prescriptions for patients with documented allergies to inactive ingredients or specific medical needs not met by commercial products. However, these exceptions cover a small minority of patients.

Can I still get compounded semaglutide from my telehealth provider?

Most telehealth providers that previously offered compounded semaglutide have transitioned their patients to compounded tirzepatide or brand-name products. Any telehealth provider still offering bulk compounded semaglutide without documented medical necessity is operating outside FDA enforcement guidelines and carries legal risk.

How do I know if tirzepatide is right for me after semaglutide?

The GLP-1 mechanism is the same, so patients who responded well to compounded semaglutide typically respond well to tirzepatide, often with greater weight loss. The main difference is that tirzepatide also activates GIP receptors. Side effects (nausea, GI issues) are similar in nature, though the titration schedule differs. Consult your prescriber and use our eligibility checker to confirm you meet criteria.

Will compounded tirzepatide also be banned?

Tirzepatide remains on the FDA drug shortage list as of April 2026, so compounding remains legal. If Eli Lilly resolves the shortage and FDA removes tirzepatide from the list, the same enforcement process that ended compounded semaglutide would apply. There is no announced timeline, but it is a risk to monitor. Check our safety center for updates.

What happens to patients on Medicare who can't get compounded semaglutide?

Medicare Part D traditionally did not cover GLP-1s for weight loss (only for diabetes). The CMS GLP-1 Bridge Demonstration Program launching July 1, 2026 is intended to provide a path to coverage for Medicare patients. See our Medicare GLP-1 coverage guide for details on the program and eligibility.

Sources